Results 81 to 90 of about 49,717 (158)

Sex Differences in Cancer Immunotherapy—Clinical Evidence and Mechanisms With a Focus on NSCLC

Immunological Reviews, Volume 338, Issue 1, March 2026.
ABSTRACT Accumulating evidence suggests that the immune system shows subtle but relevant differences between men and women. These differences may have an impact on cancer development and TME composition as well as responses to and adverse events elicited by immunotherapies.
Eva Krieghoff‐Henning, Balagopal Pai, Maike Collienne, Isabel Ben‐Batalla, Sonja Loges   +4 more
wiley   +1 more source

PS2 - 172 Preclinical Validation of a Novel CD33/CD3 Bispecific T-Cell Engager (BiTE) Antibody to Target Patient-Derived Glioblastoma Cells

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2016
P. Vora, C. Venugopal, C. Choksi, M. Qazi, J. Adams, M. London, M. Subapanditha, M. Singh, D. Bakshinyan, S. Sidhu, J. Moffat, S. Singh   +11 more
semanticscholar   +1 more source

IRAK4 Regulates NF-κB signaling to suppress CD8 + T cell activity and promote immune evasion in glioblastoma development. [PDF]

Cancer Immunol Immunother
Xue Z, Song Z, Mo L, Shi L, Yang S.
europepmc   +1 more source

Correction: Glioblastoma induces CAF-like astrocyte activation via the AKT/mTOR-SERPINH1/COL5A1 axis. [PDF]

Biomol Biomed
Zhang J, Chen Y, Xu H.
europepmc   +1 more source

Novel Adamantane-Sclareol Hybrids Exploit ROS Vulnerability to Overcome Multidrug-Resistance in Glioblastoma Cells. [PDF]

Molecules
Lupšić E, Stojković P, Grozdanić M, Terzić-Jovanović N, Pajović M, Koutsougianni F, Alexopoulou D, Opsenica IM, Pešić M, Podolski-Renić A.   +9 more
europepmc   +1 more source

Evaluation of sex differences in survival among glioblastoma patients treated with immune checkpoint inhibitors. [PDF]

Neurooncol Adv
Nakhate V, Westergaard C, Lan Z, Lasica AB, Muzikansky A, Barlow B, Russ A, Aker L, Jiao A, Pan I, Nelson TA, Nwagwu CD, Aquilanti E, Batchelor TT, Beroukhim R, Berger TR, Chukwueke U, Castro LNG, Lee EQ, Mcfaline-Figueroa JR, Nayak L, Rhee JY, Reardon DA, Huang RY, Wen PY, Youssef G.   +25 more
europepmc   +1 more source

Extent of resection and perioperative neurological status as prognostic markers in glioblastoma: a population-based study. [PDF]

J Neurooncol
Mendoza Mireles EE, Blakstad H, Server A, Leske H, Skaga E, Aarhus M, Brandal P, Helseth E, Nayak L, Rønning PA, Vik-Mo EO.   +10 more
europepmc   +1 more source

Feasibility and Safety of Autologous Dendritic Cell Vaccination Combined with Radio-Chemotherapy in Newly Diagnosed Glioblastoma: A Retrospective Single-Center Series. [PDF]

Vaccines (Basel)
Esparragosa Vázquez I, López-Díaz de Cerio A, Inoges S, Aristu J, Domínguez P, García-Eulate R, Calvo-Imirizaldu M, Arbizu J, Rodríguez-Ruiz ME, Irimia P, Alonso MM, Prósper F, Díez-Valle R, Gállego Pérez-Larraya J.   +13 more
europepmc   +1 more source

Isorhamnetin from Astragalus membranaceus exerts anti-glioma effects via PI3K/Akt signaling pathway. [PDF]

Am J Cancer Res
Luo M, Liu K, Wang Z, Li X, Wu C, Hao M, Pan Y, Zhang H, Wang Q.   +8 more
europepmc   +1 more source

Targeting Metabolic Vulnerabilities in Glioblastoma: a Framework for Multi-node Combination Therapy. [PDF]

Curr Oncol Rep
Gokani V, Kotta A, Repaka V, Rauniyar S, Noch EK.   +4 more
europepmc   +1 more source